Descrizione del progetto
Promozione della ricerca sulla terapia genica e cellulare nella Repubblica Ceca
I medicinali per terapie avanzate (ATMP) si riferiscono a terapie e trattamenti all’avanguardia che utilizzano tecnologie e tecniche innovative per affrontare malattie complesse. Gli ATMP comprendono terapie geniche e rigenerative, nonché opzioni di medicina personalizzata, solitamente mirate a malattie rare ereditarie. Finanziato dal programma ORIZZONTE, il progetto CREATIC intende creare un centro di terapia avanzata e immunoterapia nella Repubblica Ceca. Questa struttura di punta si concentrerà sui farmaci ATMP che utilizzano le scoperte della genomica, della biologia cellulare e dell’editing genico. Il centro collaborerà con i principali istituti di ricerca europei, ampliando la propria capacità di ricerca e innovazione nel campo delle terapie geniche e cellulari e allineandosi alla visione europea sui trattamenti individualizzati per le malattie rare.
Obiettivo
Progress in biomedical science enables scientists to use a whole new toolbox to treat significant groups of diseases, such as inherited rare diseases or diverse rare cancers. Advanced therapy medicinal products (ATMPs) apply recent advances in genomics, cell biology and/or gene editing to deliver truly personalized curative options. The project proposes to establish flagship ATMP-focused facility on the margin of academia and clinics: Central European Advanced Therapy and Immunotherapy Centre (CREATIC) at the Masaryk University (MU) in Brno, Czech Republic. MU will team up with the leading European research institutions: (1) Fraunhofer Institute for Cell Therapy and Immunology IZI, (2) Leipzig University, which together forms a significant cluster of research excellence in research, development and training in the fields of gene and cell therapies and (3) Copenhagen University with unique expertise in biomedical innovation law, intellectual property, biomedical ethics, privacy and regulatory framework, and health technology assessment. Combining STM and SSH disciplines the project will allow for (i) fundamental expansion of the scope of the R&I activities of all partners to build multidisciplinary excellence facilitating the delivery of ATMPs to patients who need them; (ii) establishment of the high level of decision-making autonomy for the CREATIC, which will allow significant organizational and management changes creating spirit and conditions for cutting-edge research and innovation in the Centre, and (iii) strengthen the smart specialization of the Czech Republic (RIS3 CZ 2021-2027) in the domain of Advanced medicine and drugs through the involvement of actors from the academic, public, private and societal sector. Our approach reflects research priorities and societal challenges outlined in the Pharmaceutical Strategy for Europe, which proposes ‘bedside’ manufacture of highly individualised medicines as a future trend in treating rare diseases with ATMPs.
Campo scientifico
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- medical and health sciencesmedical biotechnologycells technologies
Parole chiave
Programma(i)
Invito a presentare proposte
HORIZON-WIDERA-2022-ACCESS-01-two-stage
Vedi altri progetti per questo bandoMeccanismo di finanziamento
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinatore
601 77 Brno
Cechia